Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Surrozen Inc. Warrant (SRZNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: SRZNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.57 | 52 Weeks Range 0.01 - 0.09 | Updated Date 05/20/2025 |
52 Weeks Range 0.01 - 0.09 | Updated Date 05/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -971.62% |
Management Effectiveness
Return on Assets (TTM) -21.41% | Return on Equity (TTM) -456.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5400593 |
Shares Outstanding - | Shares Floating 5400593 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Surrozen Inc. Warrant
Company Overview
History and Background
Surrozen Inc. was a biopharmaceutical company focused on discovering and developing novel regenerative medicines. It completed a merger with Consonance Capital Acquisition Corp. II, a special purpose acquisition company (SPAC), to become publicly traded. However, Surrozen Inc. discontinued operations and initiated a wind-down process. The warrants are for the company's common stock.
Core Business Areas
- Biopharmaceutical Development: Focused on research and development of regenerative medicine therapies.
Leadership and Structure
Prior to its wind-down, Surrozen Inc. had a management team led by its CEO and a board of directors. The specific organizational structure is no longer relevant due to the company's dissolution.
Top Products and Market Share
Key Offerings
- SZN-1326: A Wnt mimetic for severe alcoholic hepatitis and other liver diseases. Clinical trials were underway but were discontinued. Market share is irrelevant given discontinuation. Potential competitors included companies developing treatments for liver diseases, such as Gilead Sciences (GILD).
- SZN-043: A Wnt mimetic for inflammatory bowel disease (IBD). Clinical trials were underway but were discontinued. Market share is irrelevant given discontinuation. Potential competitors included companies developing treatments for IBD, such as AbbVie (ABBV) and Takeda Pharmaceutical (TAK).
Market Dynamics
Industry Overview
The regenerative medicine industry is characterized by high potential and risk, involving the development of novel therapies for various diseases. It faces challenges in regulatory approval, clinical trial success, and market adoption.
Positioning
Surrozen Inc. aimed to be a leader in regenerative medicine through its Wnt mimetic platform. Its position is now irrelevant due to discontinuation of operations.
Total Addressable Market (TAM)
TAM estimates for regenerative medicine are in the billions of dollars. Surrozen Inc.'s positioning relative to TAM is no longer applicable.
Upturn SWOT Analysis
Strengths
- Novel Wnt mimetic platform (previously)
- Experienced management team (previously)
- Potential to address unmet medical needs (previously)
Weaknesses
- High cash burn rate (previously)
- Dependence on clinical trial success (previously)
- Limited revenue generation (previously)
Opportunities
- Partnerships with larger pharmaceutical companies (previously)
- Expansion of pipeline into new indications (previously)
- Advancements in regenerative medicine technologies (previously)
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Funding challenges
Competitors and Market Share
Key Competitors
- GILD
- ABBV
- TAK
Competitive Landscape
Surrozen Inc.'s competitive advantages are no longer relevant due to its discontinued operations. It failed to compete effectively against established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: No growth due to the company's relatively short lifespan and failure to achieve commercial success.
Future Projections: No future projections due to the company's wind-down.
Recent Initiatives: Recent initiatives focused on winding down operations.
Summary
Surrozen Inc. Warrant represents a speculative investment tied to a company that has ceased operations. The company's regenerative medicine approach showed promise but ultimately failed to translate into commercial success. Investors in the warrants face a high risk of losing their entire investment due to the company's wind-down and delisting. The winding down of the operations presents considerable challenges for the shareholders who could see significant loss if the warrants expire.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Market research reports (historical)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not investment advice. The value of the warrants is highly speculative and may be zero due to the company's wind-down. Historical data may no longer be relevant. The market share values for the competitor are unknown.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Surrozen Inc. Warrant
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-08-12 | CEO, President & Director Mr. Craig C. Parker M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.surrozen.com |
Full time employees 40 | Website https://www.surrozen.com | ||
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.